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Abstract
Angiogenesis  plays  a  pivotal  role  in  many  pathological  processes,  including
hepatocellular carcinoma (HCC). This indicates that antiangiogenic agents could be
promising candidates for chemoprevention against HCC. Several inhibitors targeting
receptor tyrosine kinases (RTKs) for the regulation of tumoral vascularization have
been  developed  and  employed  in  clinical  practice,  including  sorafenib.  However,
there seem to be several issues for the long-term use of this agent as some patients
have experienced adverse effects while taking sorafenib. Therefore, it is desirable for
patients with chronic liver diseases to be administered sorafenib as little as possible
by combining other safe-to-use antiangiogenic compounds. Various factors, such as
renin-angiotensin-aldosterone system (RAAS) and insulin resistance (IR), reciprocally
contribute to the promotion of angiogenesis. A blockade of RAAS with an angioten-
sin-converting  enzyme  inhibitor  (ACE-I)  or  angiotensin-II  (AT-II)  receptor  blocker
(ARB) markedly attenuates HCC in conjunction with the suppression of angiogenesis.
Moreover,  the IR status has demonstrated direct acceleration in the progression of
HCC via the augmentation of tumoral neovascularization. These findings suggest that
a combination therapy involving a lower dose of sorafenib with other clinically used
agents  [e.g.,  RAAS  blockers,  insulin  sensitizer  agents,  and  branched-chain  amino
acids (BCAA)] may reduce the adverse effects of sorafenib without attenuating the
inhibitory effect against HCC in comparison to a high-dose administration.
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1. Introduction
Angiogenesis  is  the  development  of  new vasculature  from  preexisting  blood  vessels  or
circulating endothelial cell (EC) stem cells. Emerging evidence indicates that angiogenesis
develops in many organs and under multiple pathologic situations, as well as during conditions
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of tissue growth and regeneration. Abnormal pathological angiogenesis is observed in patients
with rheumatoid arthritis, psoriasis, diabetic retinopathy, fibrogenesis, and tumor growth [1].
Although early studies were conducted to determine the molecular processes associated with
carcinogenesis and angiogenesis that were performed independently, more recent studies have
revealed that both biological phenomena emerge synergistically [2].
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second leading
cause of cancer-related mortality worldwide, accounting for more than 600,000 new cases
annually. The greatest risk factors for developing HCC include liver cirrhosis induced by
hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, excessive alcohol intake, and
metabolic syndrome. Regardless of the etiology, since HCC commonly develops in patients
with a chronic liver disease (e.g., liver cirrhosis) only approximately one-third of the patients
diagnosed with HCC are eligible for curative treatments (e.g., surgical resection) [3]. Conse-
quently, several alternative therapies have been employed, including percutaneous radiofre-
quency ablation (RFA) and transarterial chemoembolization (TACE). However, no satisfactory
improvement of HCC prognosis has been achieved to date. The notable characteristic of HCC
that accounts for its poor prognosis is the risk of high frequency in recurrence attributed to
intrahepatic metastasis or the multicentric development. The key feature of HCC progression
is also hypervascularity formed by intratumoral angiogenesis as well as the frequent recur-
rence. Several studies have demonstrated that angiogenesis is implicated in the survival and
growth of HCC. It has also been reported that angiogenesis can be induced during the early
stages of tumor formation and the various carcinogenic mechanisms have been demonstrated
in several different experimental models [4–7]. Therefore, several antiangiogenic agents (i.e.,
sorafenib) have been developed as novel treatment options for HCC.
In this chapter, mechanistic insights into angiogenesis and its contribution to hepatocarcino-
genesis will initially be reviewed. In addition, newly developed antiangiogenic agents will be
described in detail.
2. Angiogenesis in HCC
In HCC, tumor angiogenesis leads to a pathologic vascularization pattern, of which intratu-
moral vascularization is critical for the diagnosis and treatment of HCC, as well as for
pathogenesis and patient prognosis [1, 8, 9]. In general, HCC is supplied with blood flow
primarily via the hepatic arteries, while noncancerous lesions and the normal liver parenchy-
ma are supplied predominantly by the portal vein. This distinct vascularization is clinically
utilized to diagnose HCC radiographically by emphasizing the tumor lesions. Any tumor mass
more than 1–2 mm3 depends entirely on the formation of a vascular network that provides the
growing tumor with oxygen and essential nutrients [10].
Of the various proangiogenic factors, vascular endothelial growth factor (VEGF) is one of
the most potent and required for both physiological and pathological angiogenesis [11].
VEGF induces EC proliferation, promotes migration and differentiation as well as stimulates
permeabilization of blood vessels and vasculogenesis. The several forms of VEGF bind to
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two tyrosine kinase receptors, fms-like tyrosine kinase (flt-1: VEGFR-1) and the kinase insert
domain-containing receptor/murine homolog, fetal liver kinase-1 (KDR/Flk-1: VEGFR-2)
[11, 12]. Recent reports have demonstrated that upregulated VEGF expression is more
frequently observed in the tumor lesions of HCC than noncancerous lesions [13–15].
Moreover, the marked increase of VEGF expression is shown during both hepatocarcino-
genesis and HCC growth in accordance with the augmented neovascularization. Our basic
studies elucidated that monoclonal antibodies (mAb) against both VEGFR-1 and VEGFR-2
ameliorated the HCC development with antiangiogenic activity in rodents [16]. These
findings indicate that a blockade of the VEGF-VEGFR axis contributes to the suppressive
effect on HCC development.
In tumor neovascularization, VEGF often coordinates with other angiogenic pathways. The
angiopoietins (Ang) bind with receptor tyrosine kinases (RTKs) with immunoglobulin-like
and EGF-like domains (Tie1 and Tie2). Increased levels of Ang2 promote tumor angiogenesis,
metastasis, and inflammation with augmentation of VEGF activity. VEGF-A is also upregu-
lated by interaction with multiple growth factors, including fibroblast growth factor (FGF),
insulin-like growth factor-1 (IGF-1), platelet-derived growth factor (PDGF), and the trans-
forming growth factors (TGF) [17]. Tissue hypoxia also stimulates VEGF-A upregulation via
the hypoxia-inducible factors (HIF)-1α and HIF-2α [17].
3. Molecular targeted therapy
Several small-molecule, orally available RTK inhibitors exhibit an antiangiogenic effect of
inhibiting VEGF and other kinases. They are expected to have high clinical utility and are
currently being tested in clinical trials of varying stages for the treatment of advanced HCC
(Table 1).
Agent Target
Sorafenib A-RAF, B-RAF, C-RAF/Raf-1VEGFR-2, VEGFR-3, PDGFR-β, Flt-3, c-Kit
Sunitinib VEGFR-1, 2, and 3, PDGFR-α, β, c-Kit, Flt3
Brivanib VEGFR-1, 2, and 3, FGFR-1, 2, and 3
Lenvatinib VEGFR-1, 2, and 3, FGFR-1, 2, 3, and 4,PDGFR-α, c-Kit, RET
Cabozantinib VEGFR-2, MET, RET
Table 1. Molecularly targeted antiangiogenic agents for advanced HCC.
3.1. Sorafenib
Sorafenib (Nexavar®) was developed in 1995 and is the only chemotherapeutic drug that has
demonstrated to improve the survival rate in patients with HCC [18, 19]. Sorafenib acts by
inhibiting the RAF serine/threonine kinases that play a key role in the transduction of mito-
genic and oncogenic pathways through the Raf/mitogen-activated protein kinase (MEK)/
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extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK)
signaling pathway [20]. Such signaling results in a lower cyclin D1 expression as well as cell
cycle arrest. Sorafenib also potently inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3, and c-Kit,
which promote angiogenesis [19, 20]. The repression blocks a broad spectrum of different
processes involved in proliferation, angiogenesis, or apoptosis, causing a reduction in the
blood vessel regions of the tumor and the starving of cancerous cells. Furthermore, sorafenib
enhances tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell
death through an SH2 domain, which causes a tyrosine phosphatase (SHP-1)-dependent
reduction of signal transducers and activators of transcription type 3 (STAT3) phosphorylation
and the related protein myeloid cell leukemia 1 (Mcl-1) (i.e., survivin and cyclin D1) in HCC
cells [21]. Sorafenib is also able to repress Mcl-1 activity through an MAPK-independent
mechanism, which increases the intrinsic apoptosis pathway in tumor cells. Moreover, recent
studies have claimed that the eukaryotic translation initiation factor 4E (eIF4E) might be
implicated in sorafenib-dependent Mcl-1 inhibition [22]. Clinically, sorafenib can extend the
mean patient survival from 7.9 to 10.7 months [19]. Representative adverse events caused by
the treatment of sorafenib consist of diarrhea, weight loss, hand-foot skin reaction, and
hypophosphatemia. Currently, sorafenib is the first and only agent to demonstrate a beneficial
overall survival (OS) and be approved by regulators globally in patients with advanced HCC
[19].
3.2. Sunitinib
Sunitinib (Sutent®) is an oral multi-RTK inhibitor targeting VEGFR-1, 2, and 3, PDGFRs, c-Kit,
and other RTKs associated with angiogenesis [23]. Several phase II clinical trials have shown
favorable results regarding the antitumor activity of this drug against advanced HCC. In one
phase III trial, the median OS was 7.9 and 10.2 in the sunitinib and sorafenib groups, respec-
tively [24]. This indicates that sunitinib had no benefit over sorafenib as a first-line therapy for
advanced HCC.
3.3. Brivanib
Brivanib, a dual tyrosine kinase inhibitor, shows potent and selective inhibition of VEGFR and
FGFR [25]. Brivanib has exerted an anticancerous effect in xenograft human HCC models
expressing FGF receptors [26]. Two phase III trials have been performed: (1) the BRISK-FL
study, in which brivanib vs. sorafenib as first-line therapy was evaluated in patients with
advanced HCC and (2) the BRISK-PS study, in which brivanib was administered to patients
with advanced HCC who were resistant to sorafenib [27, 28]. However, both trials failed to
meet the primary endpoint of statistically improving the OS rate.
3.4. Lenvatinib
Lenvatinib (Lenvima®) is an oral multityrosine kinase inhibitor with potent antiangiogenic
effects that has recently been approved for use in differentiated thyroid cancer [29]. The drug
was established in patient-derived xenograft models that reliably recapitulated the genetic and
phenotypic features of HCC [30]. Moreover, in models expressing high levels of FGF receptor
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1, lenvatinib exhibited a greater efficacy than sorafenib. Lenvatinib has also shown highly
promising data in phase I/II clinical trials involving patients with advanced HCC [31].
3.5. Cabozantinib
Cabozantinib (Cometriq®) was approved in 2012 by the FDA and is a small-molecule RTK
inhibitor with potent activity toward VEGFR-2, MET, and RET (rearranged during transfec-
tion), leading to the inhibition of tumor angiogenesis [32]. In a phase II study, the observed
disease control rate following 12 weeks of treatment with cabozantinib was found to be 68 or
78% of the patients with or without prior sorafenib treatment exhibited tumor regression. A
phase III randomized double-blind, controlled trial is ongoing to compare the efficacy of
cabozantinib with a placebo as the second-line treatment modality for advanced HCC patients
who have previously received sorafenib.
4. Alternative therapy
Sorafenib is the standard therapeutic agent administered for the treatment of advanced stages
of HCC and it is likely that other RTK inhibitors will also become commonly utilized drugs.
However, chronic liver damage usually lowers the capacity of drug metabolism in patients,
and the long-term administration of sorafenib may induce excessive adverse effects. Therefore,
to reduce dosage of sorafenib, an alternative approach may be required to identify a clinically
available compound targeting tumor angiogenesis. Among the various factors to affect
angiogenic activities, many researchers have focused their attention on the mechanisms of
angiotensin-II (AT-II) and insulin resistance (IR). These factors have been shown to affect
angiogenesis in the liver via close interactions [33]. Moreover, since these factors could also be
involved in the HCC, the regulation of these factors might contribute to suppressing the
progression of the chronic liver disease.
4.1. RAAS blockers
The renin-angiotensin-aldosterone system (RAAS) is a hormone system that is involved in the
regulation of the plasma sodium concentration and arterial blood pressure to maintain body
fluid homeostasis [34]. Recent reports have demonstrated that RAAS is locally expressed in a
number of tissues, including the kidneys, adrenal glands, heart, vasculature and nervous
system, and liver. Actually, RAAS is frequently activated in patients with chronic liver diseases,
such as liver cirrhosis [35, 36]. AT-II is an octapeptide derived from its precursor, AT-I, after
AT-I converting enzyme (ACE) acts AT-I, proteolytically cleaving the C-terminal dipeptide.
During the progression of chronic liver diseases, AT-II is considered to be a potential mediator
of portal hypertension. It has been reported that AT-II plasma levels are clinically increased in
patients with cirrhosis, and an animal study has shown the elevation of the portal pressure by
AT-II administration [37, 38].
AT-II plays a crucial role in the development of several cancers, including HCC. Lever et al.
has previously shown the outcome of a retrospective cohort study consisting of 5207 patients
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with treatment of either an ACE inhibitor (ACE-I) or other antihypertensive agents such as
calcium channel blockers, diuretics, and β-blockers with a 10-year follow-up (Glasgow study).
Interestingly, in their study, the incidence of cancer and fetal cancer was decreased in the
patients with ACE-I treatment as compared with those with other drugs [39]. A recent cohort
study has also demonstrated a lower incidence of cancer in patients using ACE-I or an AT-II
receptor blocker (ARB) than nonusers [40]. Furthermore, it has been reported that the addition
of ACE-I or ARB provided the prolonged survival for the patients with advanced non–small
cell lung cancer undergoing platinum-based chemotherapy [41]. Additionally, inhibition of
RAAS possibly exerted the beneficial effects on the prognosis of patients with advanced
hormone-refractory prostate cancer and pancreatic cancer receiving gemcitabine [42, 43]. In
regard to liver cancer, ACE-I showed the suppressive effect on the tumor growth in a murine
HCC experimental model [44].
The RAAS, especially AT-II, is potently involved in the regulation of both rarefaction and
expansion of the vascular network. Circulating AT-II leads to drive a variety of signaling
cascades leading to VEGF, FGF, IGF, and TGF-β expression through mainly binding to the
AT1R on ECs [45–47]. AT-II/AT1-R axis plays a key role in the regulation of angiogenic activity
in various pathological events, including tumor neovascularization. Actually, inhibition of AT-
II by ACE-I and ARB reportedly attenuates intratumoral neovascularization with down-
regulation of VEGF expression in several cancers [48–50]. These findings indicate that ACE-I
and ARB can be candidates for novel antiangiogenic agents against HCC. However, previous
report has suggested that monotherapy with only antiangiogenic agent does not exert the
sufficient effect on the prognosis in patients with advanced cancer [51]. Therefore, the combi-
nation treatment of antiangiogenic agents has been approached to show a synergistic inhibi-
tory effect on cancer progression [51, 52]. For example, the combination of ACE-I and interferon
(IFN) suppressed HCC growth more potently than monotherapy with ACE-I [53]. Our report
demonstrated that the antitumoral effect of 5-fluorouracil (5-FU) is also enhanced by combi-
nation with ACE-I [54].
As well as tumor growth and metastasis, the early stages of carcinogenesis are also regulated
by RAAS-mediated angiogenesis [5, 55]. Our animal study has shown that ACE-I significantly
suppressed hepatocarcinogenesis at a clinically comparable low dose together with an
attenuated neovascularization [56]. Additionally, a combination of ACE-I with supplementa-
tion of vitamin K (VK), which is often administered to the patients with osteoporosis, showed
a more potent inhibitory effect on rat hepatocarcinogenesis than ACE-I monotherapy [57]. This
combination regimen consisting of ACE-I and VK also exhibited the beneficial effect on
ameliorating hepatocarcinogenesis in our clinical study [58]. A 48-month follow-up study
revealed that a combined ACE-I with VK significantly suppressed the cumulative recurrence
of HCC with reduced serum VEGF levels. The serum level of lectin-reactive α-fetoprotein
(AFP-L3), known as one of the HCC tumor markers, was also decreased in parallel with VEGF.
Accordingly, this combination regimen may represent a new strategy for chemoprevention
against HCC.
Aldosterone (Ald), a downstream component of AT-II in RAAS, also affects in the regulation
of angiogenesis. Endocrinologically, Ald is a mineralocorticoid hormone regulating the
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plasma sodium (Na+), the extracellular potassium (K+) and arterial blood pressure, blood
pressure, and electrolyte balance via mineralocorticoid receptors (MR) [59]. Recent data have
suggested that Ald plays a key role in endothelial dysfunction, as well as a suggested involve-
ment in the pathogenesis of hypertension [60]. Moreover, the possible involvement of Ald and
the MR systems in pathological ocular neovascularization has been reported [61]. Ald was
shown to stimulate the proliferation and tubulogenesis of EC, and exacerbated angiogenesis
in oxygen-induced retinopathy. In addition, these events could be attenuated by spironolac-
tone. Eplerenone, a selective Ald blocker (SAB), is clinically used as a novel option for the
treatment of hypertension. SAB is a selective MR antagonist with higher affinity than spiro-
nolactone, contributing to lower side effect by binding the progesterone and androgen
receptors. The animal study revealed that murine hepatocarcinogenesis was markedly
suppressed by the treatment of SAB with attenuation of VEGF-mediated angiogenesis [62].
These results indicate that SAB is also a viable option for treatment of HCC.
4.2. Regulation of insulin resistance
Recent studies have revealed a close relationship between IR and the progression of liver
disease, including HCC [63, 64]. In general, chronic liver diseases impair the metabolic
homeostasis of glucose as a result of IR, glucose intolerance, and DM [65]. Several clinical
studies have also identified the hyperinsulinemia in patients with chronic hepatitis C (CHC)
[66–68]. Experimental evidence with the HCV-transgenic mouse model confirms the contri-
bution of HCV in the development of IR and DM [69]. In this model, the overproduced TNF-
α appears to play a pivotal role in the induction of IR and DM. TNF-α is a proinflammatory
cytokine, dramatically elevated during inflammation-induced disease pathology. HCV itself
induces the phosphorylation of the serine residues associated with the insulin receptor
substrate (IRS)-1 and -2 and stimulates the overproduction of suppressor of cytokine-3
(SOC-3), inhibiting the phosphorylation of Akt/PI3K, leading to the blockade of transactivation
of GLUT-4, which contributes to inhibit intracellular glucose uptake. Additionally, nonalco-
holic fatty liver disease (NAFLD) is a common liver disorder associated with IR and DM [70].
Various factors participate in the progression of NAFLD, such as oxidative stress, endotoxemia,
obesity, genetic factors, and IR. Several reports have suggested the association of IR and
mitochondrial abnormalities [71].
Recently, a reciprocal relationship between diabetes and HCC has been noticed. A two to
threefold increase in the risk of HCC has been observed in the patients with DM, regardless
of the etiology of chronic liver diseases [72–74]. A large longitudinal study in the United States
demonstrated the twofold higher incidence of HCC in the diabetic patients [74]. Moreover, a
recent study has elucidated that the IR status directly facilitated hepatocarcinogenesis [64].
Hyperinsulinemia can generally induce the synthesis and activation of IGF-1, which has a
potential to progress a variety of cancer [75]. The altered expression pattern of IGF-1 signaling
has been found in human HCC as well as hepatocarcinogenesis in rodent models [76].
Furthermore, IR status may progress hepatocarcinogenesis through the augmentation of
hepatic neovascularization and VEGF expression in a rat carcinogenesis model [64].
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The diabetic patients with compensated liver diseases initially are treated by a lifestyle change.
However, restrictive diets may be liable to aggravate malnutrition in some patients. Thus, the
oral antidiabetic drugs are administered to treat the diabetic patients with advanced liver
diseases such as cirrhosis [77, 78]. To avoid hyperinsulinemia affecting adversely HCC growth,
the drugs exerting insulin-sensitizing effects are preferable such as metformin, pioglitazone,
dipeptidyl peptidase 4 inhibitor, or sodium glucose cotransporter inhibitor. Another report
has demonstrated that the use of statins, a class of lipid-lowering medications by inhibiting
HMG-CoA reductase that plays a central role in the production of cholesterol, significantly
lowered the risk of HCC in the patients with DM [79].
The branched-chain amino acid (BCAA), an amino acid having aliphatic side chains with a
branch (a central carbon atom bound to three or more carbon atoms), comprises three essential
amino acids: leucine, isoleucine, and valine. Several clinical studies have suggested the
beneficial effect of the long-term supplementation with BCAA granules on hypoalbuminemia
and event-free survival in the patients with cirrhosis [80, 81]. BCAAs have also been shown to
induce glucose uptake and improve glucose metabolism in a rat cirrhotic model. Intriguingly,
the animal study using obese diabetic rat showed a chemopreventive effect of BCAAs against
HCC with the downregulation of VEGF and antiangiogenic activity [82, 83]. Multicenter study
in Japan also revealed that BCAAs decreased the incidence of HCC in patients with HCV-
related cirrhosis as well as the type 2 DM and obesity [84]. However, a monotherapy with
BCAA did not inhibit the recurrence of HCC after curative treatment. Therefore, to utilize
BCAAs with sufficient effect against HCC, it is strongly recommended to combine them with
other drugs. From previous research, AT-II also plays a key role in the development of IR.
Actually, mice genetically lacking ACE exhibited the improvement of glucose tolerance
through the reduced fat mass [85]. Moreover, additional administration of ACE-I or ARB to
BCAAs is also shown to improve the IR status [33, 86]. Our randomized control trial study
demonstrated that the combined BCAAs with ACE-I suppresses the cumulative recurrence of
HCC in the patients with IR [87].
Taken together, these findings indicate that the combination of BCAAs supplementation and
RAAS blockade may represent a potentially novel therapeutic strategy against HCC in the
patients with IR.
5. Conclusions and future perspectives
Angiogenesis plays a crucial role in hepatocarcinogenesis and HCC progression, indicating
the requirement of an antiangiogenic therapy as a tool for suppressing HCC. Sorafenib has
become a breakthrough drug in the field of HCC, with an improvement in the median survival
of almost 3 months. This represents a reduction of greater than 30% for the probability of death
during the follow-up period.
However, when using RTK inhibitors, including sorafenib for patients with chronic liver
diseases, many patients exhibit adverse effects, and several symptoms are very severe. Since
the adverse effects induced by RTK inhibitors emerge in a dose-dependent manner, it is
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desirable for patients with chronic liver diseases to avoid these drugs as much as possible.
Therefore, to lower the dose of such treatments, a clinically available compound to use in
combination with RTK inhibitors may be required.
ACE-I, ARB, and SAB are extensively employed as antihypertensive agents in clinical practice
without serious adverse effects. Thus, these RAAS blocking agents may provide a novel
strategy targeting HCC. However, several reports also suggest that there is a close relationship
between AT-II polymorphisms and the progression of chronic liver diseases and cancers. In
certain types of cancers, the elevated ACE genetic polymorphisms are significantly involved
in their poor prognosis [88, 89]. Additionally, AT-II type I receptor polymorphism reportedly
contributes to the occurrence of nonalcoholic steatohepatitis (NASH) [90]. These evidences
suggest that the efficacy of RAAS inhibition may vary in each case. Since combination
treatment of ACE-I and VK exerted substantially more potent inhibitory effects, a combination
treatment involving these agents may be preferable for future clinical applications. Further-
more, under IR conditions, the combination treatment of BCAA and ACE-I would be a
promising approach against HCC via the suppression of VEGF-mediated angiogenesis. Since
these agents are widely used in clinical practice, the combination of these agents with RTK
inhibitors such as sorafenib represents a potential alternative approach against HCC.
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